OVERCOMING THE FEAR OF WOUND INFECTION

THURSDAY
29 JULY
7.30-8.30

LUXMI DHOOONMOON
NURSE CONSULTANT
TISSUE VIABILITY

SPONSORED BY: Flen Health
OBJECTIVES

To:

• Identify infection in the wound bed
• Differentiate between stages of colonisation/infection
• Understand the importance of managing infection effectively
• Discuss the use of an enzyme alginogel as an antimicrobial
WOUND INFECTION — FACTS

- Painful for the patient
- Leads to increased morbidity
- Cause of mortality
- Frequent risk of hospitalisation
- Increasing risk to society — antimicrobial resistance
- Clinical management problem
Textbook criteria of signs of infection...

- Pain
- Abscess
- Confusion
- Cellulitis
- Malodour
- Erythema
- Delayed healing/Wound breakdown
- Changes in granulation tissue
- Induration or oedema at wound edges
- Exudate — colour/texture/volume
The most up to-date IWII consensus document ‘Wound Infection in Clinical Practice.
Authored by leading experts in wound management:

Authors
- Terry Swanson, South-West Healthcare, Warrnambool, Victoria (Australia)
- Donna Angel, Royal Perth Hospital, Perth (Australia)
- Geoff Suksman, Monash University, Melbourne (Australia)
- Rose Cooper, Cardiff Metropolitan University, Cardiff (UK)
- Emily Hesler, Curtin University and Australian National University, Canberra (Australia)
- Kerri Duque, Institute of Skin Integrity and Infection Prevention, Huddersfield (UK)
- Karyn Carville, Silver Chain Group and Curtin University, Perth (Australia)
- Jacqui Flettcher, Independent Nurse Consultant (UK)
- Lindsey Kilan, University of Pennsylvania, Philadelphia, Pennsylvania (USA)
- David Keast, Lawson Health Research Institute, London, Ontario (Canada)
- David Leaper, Imperial College, London (UK)
- Greg Schultz, University of Florida, Gainesville, Florida (USA)
- Joyce Black, University of Nebraska Medical Center Omaha, Nebraska (USA)
- Evan Call, EC Service and Weber State University, Centerville, Utah (USA)

STAGES IN THE WOUND INFECTION CONTINUUM

All chronic wounds are colonised (leg ulcers, pressure ulcers and diabetic foot ulcers) up to the point of healing.

Do NOT over treat with antimicrobials.
LOCAL INFECTION

- Wounds will not heal despite ‘standard care’
- It is painful
- Strikethrough
- Local infection is contained in one location, system or structure
SPREADING INFECTION

- The invasion of the surrounding tissue by infective organisms that have spread from a wound.
- Microorganisms proliferate and spread to a degree that signs and symptoms extend beyond the wound border.
SYSTEMIC INFECTION

- It affects the body as a whole, with microorganisms spreading throughout the body via the vascular or lymphatic systems.

- Systemic inflammatory response, sepsis and organ dysfunction are signs of systemic infection.
OVERCOMING WOUND INFECTION

Once assessed and identified as being infected, a wound can be treated using the following methods:

<table>
<thead>
<tr>
<th>Method</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic antibiotics</td>
<td>These should be reserved for appropriate use</td>
</tr>
<tr>
<td>Topical antimicrobial agents</td>
<td>Useful in managing bioburden</td>
</tr>
<tr>
<td>Non-medicated dressings</td>
<td>Useful alternative to manage wound bioburden</td>
</tr>
</tbody>
</table>

Examples of antimicrobials listed are the presenter's preferred selection based on local formulary: iodine, silver, honey, polyhexamethylene biguanide (PHMB) and enzyme alginogel.
WHAT KIND OF WOUNDS DO WE SEE?

- Moisture lesions
- Skin tears
- Surgical wounds
- Fungating wounds
- Adult/child wounds
- Trauma wounds
- Pressure ulcers
- Leg ulcers
- Diabetic foot ulcers
- Burns (inc. radiotherapy burns)
## MANAGING INFECTION USING ANTIMICROBIALS

### Table 7: Topical wound infection therapies

<table>
<thead>
<tr>
<th>Antimicrobial agent</th>
<th>Type</th>
<th>Biofilm efficacy</th>
<th>Guidance for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enzyme alginate gel with two enzymes:</td>
<td>Alginate gel</td>
<td>Prevents formation of biofilms at concentration 0.5% (w/v)</td>
<td>Concentrations of alginate of 3% and 5% depending on level of exudate</td>
</tr>
<tr>
<td>Lactoperoxidase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose oxidase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iodine (povidone and cadexomer)</td>
<td>Solution</td>
<td>Inhibits development of new biofilm</td>
<td>Contraindicated in individuals sensitive to iodine or with thyroid or renal disorders</td>
</tr>
<tr>
<td>Impregnated wound dressings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder and paste</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honey</td>
<td>Medical grade</td>
<td>Inhibits biofilm growth</td>
<td>Select products that have been gamma irradiated</td>
</tr>
<tr>
<td>Honey impregnated dressings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silver</td>
<td>Salts (e.g. silver sulphadiazine, silver nitrate, silver, sulphate, silver CMC)</td>
<td>Denatures existing bacterial biofilm in concentrations over 5 μg/ml</td>
<td>Change more frequently in wounds with heavy exudate</td>
</tr>
<tr>
<td>Metallic, e.g. nanocrystalline, silver-coated nylon fibres</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impregnated wound dressings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ionic silver combined ethylenediaminetetraacetic acid (EDTA) and benzoic chloride (BEC) (antibiofilm agents)</td>
<td>Carboxymethylcellulose gelling dressing impregnated with ionic silver enhanced with EDTA and BEC</td>
<td>Combines antibiotic and antimicrobial components that work in synergy to disrupt biofilm and expose associated microorganisms to the broad-spectrum antimicrobial action of ionic silver</td>
<td>Change more frequently in wounds with heavy exudate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surfactant</td>
<td>Concentrated surfactant gels with antimicrobial preservatives</td>
<td>Prevents biofilm formation</td>
<td>Can be used between and post-debridement to prevent re-establishment of biofilm</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increases antibiotic efficacy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eradicates mature biofilm</td>
<td>May require daily application for the first few days</td>
</tr>
</tbody>
</table>
Flaminal® consists of three essential components for wound healing

| 1 | Debriding gel | The gel dissolves necrotic tissue and fibrin and absorbs them from the wound bed |
| 2 | Absorbent alginate | It contains an absorbent alginate that helps with the absorption of debris, bacteria and excess exudate |
| 3 | Antimicrobial enzyme system | It contains an antimicrobial enzyme system that protects the wound against microbial colonisation and infection |

Flaminal® can be used in all five aspects of the T.I.M.E.S. paradigm

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue</td>
<td>Continuous autolytic debridement</td>
</tr>
<tr>
<td>Infection</td>
<td>Antimicrobial protection</td>
</tr>
<tr>
<td>Moisture</td>
<td>Moist wound healing and absorbs exudate</td>
</tr>
<tr>
<td>Edge of wound</td>
<td>Safe for skin and skin tissue and protects wound edges</td>
</tr>
<tr>
<td>Surrounding skin</td>
<td>Does not damage surrounding skin</td>
</tr>
</tbody>
</table>

(Beele et al, 2012; White et al, 2014; Jones et al, 2018)
CASE STUDY ONE — PRESSURE ULCER

Patient:
- 50-year-old female, still in employment
- Multiple sclerosis, wheelchair bound

Wound:
- TVN initial assessment in community: category 4 pressure ulcer to left buttock
- High volume of exudate, malodour, no pain
- Combination of slough and unhealthy granulation in base and bone palpable
- Surrounding skin unaffected but fragile

Treatment aim:
- Reduce slough and bioburden
- Manage exudate effectively
- Improve patient’s quality of life (QOL)
- Enzyme alginogel started to reduce slough and manage exudate
CASE STUDY ONE — PRESSURE ULCER

4 weeks later

Few months later
CASE STUDY TWO — FUNGATING WOUND

Patient:
• 93-year-old female
• Atrial fibrillation
• Hypothyroidism
• Hypertension
• Squamous cell carcinoma (SCC) spreading to left side of face

Wound:
• SCC wound — fungating to left side of face
• High volume of thick exudate
• Malodorous
• Surrounding skin affected and friable — bleeds on contact
• Several bleeds as scab gets caught in dressing

Treatment aim:
• Reduce exudate and malodour
• Manage friable areas more effectively
• Improve patient’s QoL
• Enzyme alginogel started
CASE STUDY TWO — FUNGATING WOUND

**Self-care**
- Covid pandemic period
- Not keen for nurses to attend regularly
- Works with grandson who wanted to do something for patient
- Teach him how to do simple wound care
- Gentle cleaning with antimicrobial wash mitt — no rubbing
- Apply Flaminal® Forte daily to all affected areas
- No secondary dressing was required

**After 2 weeks**
- Scabs gently coming off — no bleeding
- Malodour reduced
- Minimal exudate leaking on face
- Able to eat better, as no malodour

**After 4 weeks**
- Eye was cleared and slightly opened
- Both grandson and patient were in tears
- No exudate at all
CASE STUDY THREE — EXTREME MASD

Patient:
- 87-year-old female
- Type 2 diabetes
- Hypertension, disc fusion
- Reduced mobility, recurrent falls, needs two people to transfer using equipment

Wound:
- Moisture-associated skin damage (MASD)
- Bleeding due to friable skin
- Incontinent of both urine and faeces
- Barrier cream used, carers educated on appropriate skin care regimen
- Rapid deterioration after episode of loose stool
- Surrounding skin affected and fragile

Treatment aim:
- Improve skin integrity and ease of application for carers due to incontinence
- Improve patient's QoL, ability to sit out for meal times
- Enzyme alginogel started
CASE STUDY THREE

4 weeks later

8 weeks later
CASE STUDY THREE

• Antifungal properties
• Acts as a protective barrier
• Non-cytotoxic: hence can be left on healthy skin without causing maceration
CASE STUDY FOUR — DIABETIC FOOT ULCER

Patient:
• 64-year-old male
• Type 2 diabetes for over 15 years
• Ischaemic heart disease, nephropathy, retinopathy and peripheral vascular disease

Wound:
• DFU following a neuro-ischaemic amputation of left forefoot
• High volume of exudate
• Deep sloughy wound which encompassed the whole of his forefoot to the bone
• Surrounding skin unaffected

Treatment aim:
• Reduce slough and bioburden
• Manage exudate
• Managed with simple inexpensive dressing to keep wound covered
• Enzyme alginogel started to reduce slough and manage exudate
CASE STUDY FOUR — DIABETIC FOOT ULCER

May 2013

June 2013
CASE STUDY FOUR — DIABETIC FOOT ULCER

For DFU the emphasis is on:
• Radical and repeated debridement
• Bacterial control
• Careful moisture balance to prevent maceration
• Flaminal® Forte is suitable for DFU, as it is indicated for moderate to highly exuding wounds
WHY FLAMINAL®?

- Offers antimicrobial protection
- Minimal risk for resistance development
- Debrides and removes necrotic tissue
- Self/shared care
- Ease of use in small cavities, e.g. perianal abscess/pilonidal sinus/hard-to-reach wounds
- No cytotoxicity = safe for skin tissue and protects wound edges
- Moist healing environment
- Manages exudate

(White, 2006; De Smet et al, 2009; Beele et al, 2012; Jones et al, 2018; FlenHealth, 2021)

www.flenhealth.com/fileadmin/Products/instruction_leaflets/FlaminalForte_EN_FR_NL_DE_IT.pdf
www.flenhealth.co.uk/fileadmin/Products/instruction_leaflets/FlaminalHydro_EN_FR_NL_DE_IT.pdf
GET IN TOUCH…

Scotland & Ireland
Jonathon Boyne
Regional Business Manager
E: jonathon.boyne@flenhealth.com
M: +447930954063

South East
Gerald Twinamasiko
Regional Business Manager
E: gerald.twinamasiko@flenhealth.com
M: +447930953484

South West
Adam Page
Regional Business Manager
E: adam.page@flenhealth.com
M: +447930953835

The North & Midlands
Lewis Hampshire
Regional Business Manager
E: lewis.hampshire@flenhealth.com
M: +447930953847

Please get in touch to find out more or request a free sample.
Visit our website: https://www.flenhealth.co.uk/ or email us at info@flenhealth.com
REFERENCES

- Flaminal® Hydro instructions for use. Available online: www.flenhealth.co.uk/fileadmin/Products/instruction_leaflets/FlaminalHydro_EN_FR_NL_DE_IT.pdf
- Flaminal® Forte instructions for use. Available online: www.flenhealth.com/fileadmin/Products/instruction_leaflets/FlaminalForte_EN_FR_NL_DE_IT.pdf